Literature DB >> 17338879

[Comparison of the REGICOR and SCORE function charts for classifying cardiovascular risk and for selecting patients for hypolipidemic or antihypertensive treatment].

Francisco Buitrago1, Lourdes Cañón-Barroso, Natalio Díaz-Herrera, Eloísa Cruces-Muro, Miguel Escobar-Fernández, José M Serrano-Arias.   

Abstract

INTRODUCTION AND
OBJECTIVES: In Spain, use of the Framingham-REGICOR (Registre Gironí del Cor) and SCORE (Systematic Coronary Risk Evaluation) risk charts is recommended for stratifying cardiovascular disease risk. The aims of the present study were to evaluate the degree of agreement between these charts when used to evaluate cardiovascular disease risk in nondiabetic individuals aged 40-65 years and to estimate the percentage of patients recommended for hypolipidemic or antihypertensive treatment.
METHODS: The study included 608 nondiabetic patients aged between 40-65 years (mean 52.8 years, 56.7% female) with no evidence of cardiovascular disease who were attending a primary healthcare center between 1990-1994. REGICOR and SCORE equations were used to calculate 10-year cardiovascular disease risks. Patients were classified as high-risk if their risk was > or =10% with REGICOR or > or =5% with SCORE.
RESULTS: Some 7.9% of the population was classified as high-risk with REGICOR and 9.2%, with SCORE (P=.41). Only 2.6% and 2.9% (P=.81) of women were classified as high-risk, compared with 14.8% and 17.5% of men, with REGICOR and SCORE, respectively (P=.40). The kappa coefficient was 0.45. According to European professional society guidelines, 23.8% of patients classified by SCORE and 23.0% classified by REGICOR (P=.73) would be recommended hypolipidemic treatment, while 31.2% and 31.7% (P=.85), respectively, would be recommended antihypertensive treatment.
CONCLUSIONS: There was moderately good agreement between REGICOR and SCORE charts when used to evaluate nondiabetic individuals aged 40-65 years. They identified similar percentages of patients who would be recommended for hypolipidemic or antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17338879

Source DB:  PubMed          Journal:  Rev Esp Cardiol        ISSN: 0300-8932            Impact factor:   4.753


  6 in total

1.  Original and REGICOR Framingham functions in a nondiabetic population of a Spanish health care center: a validation study.

Authors:  Francisco Buitrago; Juan Ignacio Calvo-Hueros; Lourdes Cañón-Barroso; Gerónimo Pozuelos-Estrada; Luis Molina-Martínez; Manuel Espigares-Arroyo; Juan Antonio Galán-González; Francisco J Lillo-Bravo
Journal:  Ann Fam Med       Date:  2011 Sep-Oct       Impact factor: 5.166

2.  Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk.

Authors:  Antonio Rodriguez-Poncelas; Gabriel Coll-de-Tuero; Marc Saez; José M Garrido-Martín; José M Millaruelo-Trillo; Joan Barrot de-la-Puente; Josep Franch-Nadal
Journal:  BMC Cardiovasc Disord       Date:  2015-10-13       Impact factor: 2.298

3.  A 10- and 15-year performance analysis of ESC/EAS and ACC/AHA cardiovascular risk scores in a Southern European cohort.

Authors:  Cátia Santos-Ferreira; Rui Baptista; Manuel Oliveira-Santos; José Pereira Moura; Lino Gonçalves
Journal:  BMC Cardiovasc Disord       Date:  2020-06-19       Impact factor: 2.298

4.  Agreement between the SCORE and D'Agostino Scales for the classification of high cardiovascular risk in sedentary spanish patients.

Authors:  Manuel A Gómez-Marcos; Gonzalo Grandes; José A Iglesias-Valiente; Alvaro Sánchez; Imanol Montoya; Luis García-Ortiz
Journal:  Int J Environ Res Public Health       Date:  2009-11-11       Impact factor: 3.390

5.  Therapeutic implications of selecting the SCORE (European) versus the D'AGOSTINO (American) risk charts for cardiovascular risk assessment in hypertensive patients.

Authors:  Manuel A Gómez-Marcos; Carlos Martínez-Salgado; Carlos Martin-Cantera; José I Recio-Rodríguez; Yolanda Castaño-Sánchez; Maria Giné-Garriga; Emiliano Rodriguez-Sanchez; Luis García-Ortiz
Journal:  BMC Cardiovasc Disord       Date:  2009-05-11       Impact factor: 2.298

6.  SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis.

Authors:  Carmen Gómez-Vaquero; Alfonso Corrales; Andrea Zacarías; Javier Rueda-Gotor; Ricardo Blanco; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.